NCT00918606 is a Phase 1 clinical trial of LIPO-102 in Subcutaneous Adipose Tissue Reduction, sponsored by Neothetics, Inc.

Who is sponsoring NCT00918606?

NCT00918606 is sponsored by Neothetics, Inc.

What drugs are being tested in NCT00918606?

Interventions in NCT00918606: LIPO-102.

What condition does NCT00918606 study?

NCT00918606 studies Subcutaneous Adipose Tissue Reduction.

Is NCT00918606 still recruiting?

NCT00918606 is currently completed. Last updated 19 March 2015.

Last reviewed 2015-03-19 · How we verify

NCT00918606

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers

Completed Phase 1 Last updated 19 March 2015

What this trial tests

Phase 1 trial testing LIPO-102 in Subcutaneous Adipose Tissue Reduction in 30 participants. Completed in 1 June 2009.

Timeline

1 February 2009

Primary endpoint
1 June 2009

1 June 2009

Quick facts

Lead sponsor	Neothetics, Inc
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 February 2009
Primary completion	1 June 2009
Estimated completion	1 June 2009
Sites	1 location across United States

Drugs / interventions tested

LIPO-102 — full drug profile →

Conditions studied

Subcutaneous Adipose Tissue Reduction — all drugs for Subcutaneous Adipose Tissue Reduction →

Sponsor

Neothetics, Inc — full company profile →

Who can join

Adults 18 to 55, any sex, with Subcutaneous Adipose Tissue Reduction. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety: Laboratory tests, medical exams
Time frame: 4 weeks

Sponsor's own description

An Evaluation of the PK and Safety of LIPO-102 in Healthy Volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Neothetics, Inc trials

Trials by the same sponsor.

NCT03005717 — Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00918606 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neothetics, Inc
Last refreshed: 19 March 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00918606.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing